Latest filing published 28 Nov 2023 for Hepion Pharmaceuticals, Inc., €6,970.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -78.1%Entry US$152.75 · Close at T+365 US$33.40
- -87.2%Entry US$272.50 · Close at T+365 US$34.95
- -56.3%Entry US$2,310.00 · Close at T+365 US$1,010.00
- -38.8%Entry US$2,190.00 · Close at T+365 US$1,340.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Peter Wijngaard: trading record in brief
Filings by Peter Wijngaard span 2 companies, the busiest being Medicines Co /DE and Hepion Pharmaceuticals, Inc. In total, 18 filings cover trades dated from 30 August 2019 to 27 November 2023.
No open-market sale appears; the market trades are 8 purchases worth €79k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 2 share grants and 7 option exercises. So far in 2023, the count stands at 6 purchases and no sales.
Half of the purchases are above €6,220 and half below. Clusters matter here: 4 out of 5 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -25.5%. This is a record of the past, not a forecast.
Most recently, on 28 November 2023, the filings show an open-market purchase worth €6,970 in Hepion Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Peter Wijngaard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,500 shares@ US$3.05Common StockSEC:0001104659-23-121427:1Canonical exit: 25 Feb 2024 (T+90)
- 2,500 shares@ US$3.0956.4% of flowCommon StockSEC:0001104659-23-121427:0Canonical exit: 22 Feb 2024 (T+90)
- 139 shares@ US$5.450.0% of flowCommon StockSEC:0001104659-23-102209:1Canonical exit: 14 Dec 2023 (T+90)
- 861 shares@ US$5.37Common StockSEC:0001104659-23-102209:2Canonical exit: 14 Dec 2023 (T+90)
- 1,000 shares@ US$5.64Common StockSEC:0001104659-23-102209:3Canonical exit: 18 Dec 2023 (T+90)
- 1,000 shares@ US$5.8243.6% of flowCommon StockSEC:0001104659-23-102209:0Canonical exit: 14 Dec 2023 (T+90)
- 10,000 shares@ US$2.2029.3% of flowCommon StockSEC:0001104659-21-025200:0Canonical exit: 17 May 2021 (T+90)
- 20,000 shares@ US$1.9171.3% of flowCommon StockSEC:0001104659-20-137755:0Canonical exit: 18 Mar 2021 (T+90)
- 107,546 sharesCommon StockSEC:0000950142-20-000051:0
- 50,189 shares@ US$52.709.0% of flowCommon StockSEC:0000950142-19-002604:0
- 18,000 shares@ US$33.272.0% of flowCommon StockSEC:0000950142-19-002604:1
- 26,250 shares@ US$29.012.6% of flowCommon StockSEC:0000950142-19-002604:2
- 35,000 shares@ US$29.013.5% of flowCommon StockSEC:0000950142-19-002604:3
- 70,000 shares@ US$29.016.9% of flowCommon StockSEC:0000950142-19-002604:4
- 5,000 shares@ US$29.010.5% of flowCommon StockSEC:0000950142-19-002604:5
- 125,000 shares@ US$25.4110.8% of flowCommon StockSEC:0000950142-19-002604:6
- 224,341 shares@ US$84.7864.7% of flowCommon StockSEC:0000950142-19-002604:7
- 491 shares@ US$21.600.0% of flowCommon StockSEC:0001179110-19-010063:0
18 of 18 declarations
